Recently, Euretos was featured in one of the country’s leading financial newspapers, Het Financieele Dagblad (FD). Here, Aram Krol, CEO of Euretos, explained the Euretos Augmented Intelligence approach that can help reduce risk in the drug discovery and development process.
One of the areas where Euretos applies AI is in data integration. It uses so-called machine reading technology to interpret and connect hundreds of public biomolecular databases and millions of scientific publications. This results in the largest AI integrated knowledge base where multi-omics data is interlinked to literature, patents, experimental and clinical evidence.
The key point we make is that AI, in our view, should be viewed fundamentally as Augmented Intelligence supporting the human endeavor of scientific research. From our inception we have therefore focused on creating an online cloud platform that is easy to use, enabling researchers to draw their own, evidence-based conclusions supported by AI.
A good example of this Augmented Intelligence approach is the recent Health Holland funded ‘Trusted World of Corona’ consortium consisting of 13 partners including the Leiden University Medical Centre (LUMC), the Leiden Academic Centre for Drug Research (LACDR), the Human Vaccines Project (HVP) and Roche.
Here, one of the key aims is to create a Covid19 disease model which is based on real-world and clinical observations and rationalized and validated by Covid19 disease experts and clinicians. The Euretos AI Platform plays a central role in this rationalization process and is the initial starting point for creating the Covid19 computational disease model.
Source: Analyse Nederland